- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05572515
Studie porovnávající monoterapii teclistamabem versus pomalidomid, bortezomib, dexamethason (PVd) nebo karfilzomib, dexamethason (Kd) u účastníků s relapsem nebo refrakterním mnohočetným myelomem (MajesTEC-9)
Randomizovaná studie fáze 3 porovnávající monoterapii teclistamabem s pomalidomidem, bortezomibem, dexamethasonem (PVd) nebo karfilzomibem, dexamethasonem (Kd) u účastníků s relapsem nebo refrakterním mnohočetným myelomem, kteří dostali 1 až 3 předchozí linie anti-CD, včetně 3CD monoterapie a lenalidomid
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Rozšířený přístup
Kontakty a umístění
Studijní místa
-
-
-
Blacktown, Austrálie, 2148
- Blacktown Hospital
-
Fitzroy, Austrálie, 3065
- St Vincents Hospital Melbourne
-
Melbourne, Austrálie, 3128
- Box Hill Hospital
-
Murdoch, Austrálie, 6150
- Fiona Stanley Hospital
-
Nedlands, Austrálie, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Brasschaat, Belgie, 2930
- Algemeen Ziekenhuis Klina
-
Haine-St-Paul, Belgie, 7100
- Jolimont
-
Kortrijk, Belgie, 8500
- Az Groeninge
-
Leuven, Belgie, 3000
- Universitair Ziekenhuis Gasthuisberg
-
Liège, Belgie, 4000
- CHR de la Citadelle
-
-
-
-
-
Brasília, Brazílie, 70390-140
- Hospitais Integradaos da Gavea S/A - DF Star
-
Caxias do Sul, Brazílie, 95070 560
- Fundacao Universidade de Caxias do Sul
-
Curitiba, Brazílie, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Joinville, Brazílie, 89201-260
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, Brazílie, 59062 000
- Liga Norte Riograndense Contra O Cancer
-
Niterói, Brazílie, 24020-073
- Complexo Hospitalar de Niteroi
-
Rio de Janeiro, Brazílie, 22775-001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador, Brazílie, 41253-190
- IDOR - Regional Bahia
-
São José do Rio Preto, Brazílie, 15090-000
- Funfarme Sjrp
-
São Paulo, Brazílie, 05652-900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brazílie, 01323-001
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Brazílie, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brazílie, 01308-901
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
São Paulo, Brazílie, 04537 081
- Clinica Medica Sao Germano LTDA
-
São Paulo, Brazílie, 01401 002
- IDOR - Regional Sao Paulo
-
São Paulo, Brazílie, 01321-001
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Aalborg, Dánsko, 9000
- Aalborg University Hospital
-
Aarhus, Dánsko, 8200
- Aarhus University Hospital
-
Copenhagen, Dánsko, DK-2100
- Rigshospitalet
-
Herning, Dánsko, 7400
- Regionshospitalet Godstrup
-
Odense C, Dánsko, 5000
- Odense Universitetshospital
-
Vejle, Dánsko, 7100
- Vejle Sygehus
-
-
-
-
-
Amiens, Francie, 80000
- CHU Amiens - Hopital Sud
-
Caen, Francie, 14000
- Hôpital Côte de Nacre
-
Grenoble, Francie, 38700
- CHU Grenoble
-
Le Mans, Francie, 72037
- Centre Hospitalier du Mans
-
Lille, Francie, 59020
- Hopital Saint Vincent de Paul
-
Montpellier, Francie, 34295 cede
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, Francie, 44000
- CHU Nantes
-
Paris, Francie, 75743
- Hopital Necker Enfants Malades
-
Paris, Francie, 75012
- Hopital Saint-Antoine
-
Paris, Francie, 75013
- Hopital de la Pitie Salpetriere
-
Toulouse, Francie, 31100
- Institut Universitaire du Cancer Toulouse Oncopole
-
Vandœuvre-lès-Nancy, Francie, 54500
- CHU de Nancy - Hopital de Brabois
-
-
-
-
-
Amersfoort, Holandsko, 3813 TZ
- Meander Medisch Centrum
-
Amsterdam, Holandsko, 1081 HV
- VUMC Amsterdam
-
Groningen, Holandsko, 9700 RB
- Universitair Medisch Centrum Groningen
-
Utrecht, Holandsko, 3584 CX
- UMC Utrecht
-
-
-
-
-
Gūrgaon, Indie, 122002
- Fortis Memorial Research Institute
-
Jaipur, Indie, 302017
- Bhagwan Mahaveer Cancer Hospital & Research Centre
-
Pune, Indie, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
-
-
-
-
Bologna, Itálie, 40138
- A O U Sant Orsola Malpighi
-
Milan, Itálie, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Palermo, Itálie, 90127
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Pisa, Itálie, 56126
- Ospedale Santa Chiara AO Universitaria Pisana
-
Reggio Emilia, Itálie, 42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma, Itálie, 00128
- Campus Bio Medico di Roma
-
Siena, Itálie, 53100
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
Turin, Itálie, 10126
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
Udine, Itálie, 33100
- ASUI Santa Maria della Misericordia di Udine
-
Varese, Itálie, 21100
- Ospedale di Circolo e Fondazione Macchi
-
-
-
-
-
Hadera, Izrael, 3810101
- Hillel Yaffe Medical Center
-
Haifa, Izrael, 31048
- Bnai Zion Medical Center
-
Haifa, Izrael, 3436212
- Carmel Medical Center
-
Petah Tikva, Izrael, 49100
- Rabin Medical Center
-
Ramat Gan, Izrael, 52621
- Sheba Medical Center
-
Tel Aviv, Izrael, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bunkyō City, Japonsko, 113 8519
- Institute of Science Tokyo Hospital
-
Chiba, Japonsko, 260-8717
- Chiba Cancer Center
-
Gifu, Japonsko, 503-8502
- Ogaki Municipal Hospital
-
Gunma, Japonsko, 377-0280
- National Hospital Organization Shibukawa Medical Center
-
Hirakata, Japonsko, 573 1191
- Kansai Medical University Hospital
-
Hitachi, Japonsko, 317-0077
- Hitachi General Hospital
-
Iruma-gun, Japonsko, 350-0495
- Saitama Medical University Hospital
-
Kamogawa, Japonsko, 296-8602
- Kameda Medical Center
-
Kashiwa, Japonsko, 277 8577
- National Cancer Center Hospital East
-
Kurashiki, Japonsko, 710-8602
- Kurashiki Central Hospital
-
Matsuyama, Japonsko, 790-8524
- Matsuyama Red Cross Hospital
-
Nagakute, Japonsko, 480-1195
- Aichi Medical University Hospital
-
Nagasaki, Japonsko, 852-8511
- JRC Nagasaki Genbaku Hospital
-
Niigata, Japonsko, 951 8520
- Niigata University Medical And Dental Hospital
-
Okayama, Japonsko, 701-1192
- National Hospital Organization Okayama Medical Center
-
Osaka, Japonsko, 545 8586
- Osaka Metropolitan University Hospital
-
Sapporo, Japonsko, 060-8648
- Hokkaido University Hospital
-
Tokyo, Japonsko, 113-0033
- Juntendo University Hospital
-
Tokyo, Japonsko, 135 8550
- The Cancer Institute Hospital of JFCR
-
Yamagata, Japonsko, 990 2331
- Yamagata University Hospital
-
Yamanashi, Japonsko, 400-8506
- Yamanashi Prefectural Central Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
New Brunswick
-
Saint John, New Brunswick, Kanada, E2L 4L2
- Saint John Regional Hospital
-
-
Ontario
-
Brampton, Ontario, Kanada, L6R 3J7
- Brampton Civic Hospital
-
Oshawa, Ontario, Kanada, L1G2B9
- Lakeridge Health Oshawa
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T 2M4
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
-
-
-
-
-
George Town, Malajsie, 10450
- Hospital Pulau Pinang
-
Kota Kinabalu, Malajsie, 88200
- Hospital Queen Elizabeth
-
Kuala Lumpur, Malajsie, 59100
- University Malaya Medical Centre
-
Subang Jaya, Malajsie, 47500
- Subang Jaya Medical Centre
-
-
-
-
-
Cottbus, Německo, 03048
- Medizinische Universitat Lausitz Carl Thiem
-
Dresden, Německo, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Greifswald, Německo, 17475
- Universitätsmedizin Greifswald
-
Hamburg, Německo, 22763
- Asklepios Klinik Altona
-
Heidelberg, Německo, 69120
- Universitaetsklinikum Heidelberg
-
Marburg, Německo, 35043
- Universitaetsklinikum Giessen und Marburg GmbH
-
Tübingen, Německo, 72076
- Universitatsklinikum Tubingen
-
Ulm, Německo, 89070
- Universitatsklinikum Ulm
-
Zwickau, Německo, 08060
- Heinrich-Braun-Klinikum gGmbH
-
-
-
-
-
Gdansk, Polsko, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Katowice, Polsko, 40 519
- Pratia Onkologia Katowice
-
Kielce, Polsko, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Lublin, Polsko, 20-081
- Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
-
-
-
-
-
Almada, Portugalsko, 2805-267
- Uls Almada Seixal - Hosp. Garcia de Orta
-
Braga, Portugalsko, 4710-243
- Uls Braga - Hosp. Braga
-
Lisbon, Portugalsko, 1400-038
- Champalimaud Foundation Champalimaud Centre
-
Porto, Portugalsko, 4200072
- Instituto Portugues de Oncologia
-
Vila Nova de Gaia, Portugalsko, 4434-502
- Uls Gaia Espinho
-
-
-
-
-
Salzburg, Rakousko, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Rakousko, A-1090
- Medical University Vienna MUV
-
-
-
-
-
Aberdeen, Spojené království, AB25 2ZN
- Aberdeen Royal Infirmary
-
Birmingham, Spojené království, B15 2GW
- University Hospitals Birmingham NHS Foundation Trust
-
Colchester, Spojené království, CO4 5JL
- Colchester Hospital University NHS
-
Liverpool, Spojené království, L7 8YA
- The Clatterbridge Cancer Centre
-
London, Spojené království, SW17 0QT
- St Georges Hospital
-
London, Spojené království, SW10 9NH
- Chelsea And Westminster Hospital
-
Middlesbrough, Spojené království, Ts4 3Bw
- James Cook University Hospital
-
Norwich, Spojené království, NR4 7UY
- Norfolk and Norwich University Hospital
-
Staffordshire, Spojené království, ST4 6QG
- Royal Stoke University Hospital
-
-
-
-
Alaska
-
Anchorage, Alaska, Spojené státy, 99508
- Alaska Oncology and Hematology LLC
-
-
Arizona
-
Gilbert, Arizona, Spojené státy, 85234
- Banner MD Anderson Cancer Center
-
-
California
-
Berkeley, California, Spojené státy, 94704
- Alta Bates Comprehensive Cancer Center
-
Long Beach, California, Spojené státy, 90806
- MemorialCare Long Beach Medical Center
-
Orange, California, Spojené státy, 92868
- University of California Irvine
-
Whittier, California, Spojené státy, 90602
- PIH Health Hospital
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Farmington, Connecticut, Spojené státy, 06030
- University of Connecticut
-
-
Florida
-
Miami, Florida, Spojené státy, 33136
- University of Miami Sylvester Cancer Center
-
Orlando, Florida, Spojené státy, 32806
- Orlando Health Cancer Institute
-
Weston, Florida, Spojené státy, 33331
- Cleveland Clinic Florida
-
-
Iowa
-
Waukee, Iowa, Spojené státy, 50263
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, Spojené státy, 70006
- East Jefferson General Hospital Bone Marrow Transport Clinic
-
-
Maryland
-
Bethesda, Maryland, Spojené státy, 20889
- Walter Reed National Military Medical Center
-
Silver Spring, Maryland, Spojené státy, 20904
- Maryland Oncology Hematology P A
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02118
- Boston University Medical Center
-
-
Missouri
-
Chesterfield, Missouri, Spojené státy, 63017
- Saint Lukes Hospital Saint Lukes Cancer Specialists
-
-
New Jersey
-
Camden, New Jersey, Spojené státy, 08103
- Cooper Health System MD Anderson Cancer Center at Cooper
-
-
New York
-
New York, New York, Spojené státy, 10032
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27705
- Durham VAMC
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Spojené státy, 17601
- Penn Medicine Lancaster General Health
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37203
- Tennessee Oncology
-
-
Texas
-
Fort Sam Houston, Texas, Spojené státy, 78234
- Brooke Army Medical Center
-
Houston, Texas, Spojené státy, 77030
- Baylor College of Medicine
-
Houston, Texas, Spojené státy, 77030
- Michael E DeBakey VA Medical Center
-
Houston, Texas, Spojené státy, 77054
- Harris Health Smith Clinic
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Fort Belvoir, Virginia, Spojené státy, 22060
- Alexander T. Augusta Military Medical Center
-
Norfolk, Virginia, Spojené státy, 23502
- Virginia Oncology Associates
-
-
Washington
-
Tacoma, Washington, Spojené státy, 98405
- NorthWest Medical Specialties, PLLC
-
-
-
-
-
Ankara, Turecko (Türkiye), 06200
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turecko (Türkiye), 06680
- Liv Hospital Ankara
-
Ankara, Turecko (Türkiye), 06620
- Ankara University Medical Faculty
-
Ankara, Turecko (Türkiye), 06010
- Ankara Gulhane Training and Research Hospital
-
Antalya, Turecko (Türkiye), 07100
- Antalya Training And Research Hospital
-
Denizli, Turecko (Türkiye), 20070
- Pamukkale University Medical Faculty
-
Istanbul, Turecko (Türkiye), 34214
- Medipol Mega Universite Hastanesi
-
Samsun, Turecko (Türkiye), 55280
- Ondokuz Mayis University
-
-
-
-
-
Brno, Česko, 625 00
- Fakultni nemocnice Brno
-
Olomouc, Česko, 779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba, Česko, 708 52
- Fakultni Nemocnice Ostrava
-
Prague, Česko, 128 08
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Beijing, Čína, 100020
- Beijing Chaoyang Hospital
-
Beijing, Čína, 102208
- BeiJing JiShuiTan Hospital
-
Changchun, Čína, 130021
- The First Bethune Hospital of Jilin University
-
Changsha, Čína, 410013
- The Third Xiangya Hospital, Central South University
-
Chengdu, Čína, 610032
- Sichuan Provincial Peoples Hospital
-
Chongqing, Čína, 400030
- Chongqing University Cancer Hospital
-
Fuzhou, Čína, 350001
- Fujian Meidical University Union Hospital
-
Guangzhou, Čína, 511363
- Sun Yat -Sen University Cancer Center
-
Hangzhou, Čína, 310003
- First affiliated Hospital of Zhejiang University
-
Hangzhou, Čína, 310003
- First affiliated Hospital of Zhejiang University 1
-
Harbin, Čína, 150000
- Harbin medical university cancer hospital
-
Nanchang, Čína, 330006
- The First Affiliated Hospital of NanChang University
-
Nanjing, Čína, 210008
- Nanjing Drum Tower Hospital
-
Nanning, Čína, 530021
- First Affiliated Hospital of Guangxi Medical University
-
Shanghai, Čína, 200434
- Shanghai Fourth People s Hospital
-
Shenyang, Čína, 110055
- Shengjing Hospital Of China Medical University
-
Shenzhen, Čína, 518025
- Shenzhen 2nd People's Hospital
-
Tianjin, Čína, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Čína, 301617
- Institute of Hematology and Blood Diseases Hospital
-
Wenzhou, Čína, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Čína, 430023
- Wuhan Union Hospital
-
Wuxi, Čína, 214023
- Wuxi People s Hospital
-
Xi'an, Čína, 710004
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Zhengzhou, Čína, 450008
- Henan Cancer Hospital
-
-
-
-
-
Athens Attica, Řecko, 115 28
- Alexandra General Hospital of Athens
-
Pátrai, Řecko, 263 35
- Agios Andreas General Hospital of Patra
-
Thessaloniki, Řecko, 570 10
- G Papanikolaou Hospital of Thessaloniki
-
-
-
-
-
Badalona, Španělsko, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Jerez de la Frontera, Španělsko, 11407
- Hosp. de Jerez de La Frontera
-
L'Hospitalet de Llobregat, Španělsko, 08908
- Institut Catala d Oncologia L Hospitalet
-
León, Španělsko, 24008
- Hosp. de Leon
-
Madrid, Španělsko, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Španělsko, 28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Španělsko, 28031
- Hosp. Univ. Infanta Leonor
-
Murcia, Španělsko, 30008
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Oviedo, Španělsko, 33011
- Hospital Universitario Central de Asturias
-
Palma de Mallorca, Španělsko, 07198
- Hosp. Son Llatzer
-
Pontevedra, Španělsko, 36071
- Hosp. Montecelo
-
Pozuelo de Alarcón, Španělsko, 28223
- Hosp. Quiron Madrid Pozuelo
-
Valencia, Španělsko, 46026
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
Falun, Švédsko, 791 82
- Falu Lasarett Medicinkliniken Falun
-
Helsingborg, Švédsko, 25287
- Helsingborgs lasarett
-
Uppsala, Švédsko, 751 85
- Akademiska Sjukhuset
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
- Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
- Must be willing and able to adhere to the lifestyle restrictions specified in this protocol
Exclusion Criteria:
- Received any prior B cell maturation antigen (BCMA)-directed therapy
- A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
- Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization
- Received a live, attenuated vaccine within 4 weeks before randomization
- Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
- Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Teclistamab
Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study. |
Teclistamab will be administered subcutaneously.
Ostatní jména:
|
|
Experimentální: Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)
Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study. Participants who are still receiving the treatment and benefiting from it may enter the LTE and DA-LTE Phases to continue their current treatment until end of the study. |
Pomalidomide will be administered orally. Carfilzomib will be administered intravenously. Bortezomib will be administered subcutaneously. Dexamethasone will be administered orally in PVd and intravenously or orally in Kd. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Part 1: Progression-free Survival (PFS)
Časové okno: Up to 9 years
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
Časové okno: Up to 9 years
|
Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to [>=] 38°C); Grade 2: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature >=38°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death. |
Up to 9 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Part 1 and 2: Overall Response (Partial Response [PR] or Better)
Časové okno: Up to 9 years
|
Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
Časové okno: Up to 9 years
|
VGPR or better (Stringent Complete Response [sCR]+Complete Response [CR]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1 and 2: Complete Response (CR) or Better Response
Časové okno: Up to 9 years
|
CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1: Duration of Response (DOR)
Časové okno: Up to 9 years
|
DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Time to Next Treatment (TTNT)
Časové okno: Up to 9 years
|
TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment. |
Up to 9 years
|
|
Part 1: Progression-free Survival on Next-line Therapy (PFS2)
Časové okno: Up to 9 years
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Overall Survival (OS)
Časové okno: Up to 9 years
|
OS is defined as the time from the date of randomization to the date of the participant's death due to any cause. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
Časové okno: Up to 9 years
|
Number of participants with AEs by Severity will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
Časové okno: Up to 9 years
|
Number of participants with SAEs by Severity will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Abnormal Laboratory Results
Časové okno: Up to 9 years
|
Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported. |
Up to 9 years
|
|
Part 1 and 2: Serum Concentrations of Teclistamab
Časové okno: Up to 9 years
|
Serum concentrations of teclistamab will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
Časové okno: Up to 9 years
|
Number of participants with ADAs to teclistamab will be reported. |
Up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Časové okno: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
Časové okno: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Časové okno: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Časové okno: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 9 years
|
|
Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
Časové okno: Up to 9 years
|
Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change. |
Up to 9 years
|
|
Part 1: PFS in Participants in High-risk Molecular Features
Časové okno: Up to 9 years
|
PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Depth of Response in Participants in High-risk Molecular Features
Časové okno: Up to 9 years
|
Depth of response in participants in high-risk molecular features will be reported. |
Up to 9 years
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Cévní onemocnění
- Kardiovaskulární choroby
- Novotvary
- Onemocnění imunitního systému
- Novotvary podle histologického typu
- Hematologická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Novotvary, plazmatické buňky
- Hemostatické poruchy
- Paraproteinémie
- Poruchy krevních bílkovin
- Hemoragické poruchy
- Hemická a lymfatická onemocnění
- Mnohočetný myelom
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Polycyklické sloučeniny
- Anorganické chemikálie
- Těhotenství
- Těhotenství
- Steroidy
- Sloučeniny roztaveného kruhu
- Steroidy, fluorované
- Těhotenství
- Kyseliny boronové
- Kyseliny, nekarboxylové
- Kyseliny
- Boronové sloučeniny
- Pyraziny
- Bortezomib
- Dexamethason
- Carfilzomib
- Pomalidomid
Další identifikační čísla studie
- CR109244
- 64007957MMY3006 (Jiný identifikátor: Janssen Research & Development, LLC)
- 2022-000928-37 (Číslo EudraCT)
- 2023-503444-13-00 (Identifikátor registru: EUCT number)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .